FXM Research Miramar — research payments reported

By program year

2 rows

Year	Kind	Amount	Payments
2020	Research	$11,008	3
2019	Research	$321,593	30

Breakdown

Who paid Research payments · program years 2019–2020

Taro Pharmaceuticals USA, Inc. $301,110 27 payments
Dr.Reddy's Laboratories,Inc. $28,128 4 payments
Vanda Pharmaceuticals Inc. $3,300 1 payment
Eli Lilly and Company $63 1 payment

Studies the money was for Research payments · program years 2019–2020

BTCG 1808 $283,565 23 payments
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis $28,128 4 payments
An Open-Label Study to Assess the Efficacy and Potential for Adrenal Suppression Following Maximal Use Treatment With TA-102 Topical Formulations in Subjects With Plaque Psoriasis $10,945 2 payments
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris $3,600 1 payment
Evaluating the Effects of Tradipitant Vs. Placebo in Atopic Dermatitis $3,300 1 payment
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris $3,000 1 payment
A Multicenter, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of Ly3074828 in Patients With Moderate-To-Severe Plaque Psoriasis Oasis-3 $63 1 payment

What the money was spent on Research payments · program years 2019–2020

Professional salary support $280,910 21 payments
Other $17,200 5 payments
Overhead $3,000 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.